RITUXIMAB TREATMENT EFFICACY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS REFRACTORY TO STANDARD THERAPY IN THE LONG-TERM FOLLOW-UP
https://doi.org/10.14412/1995-4484-2014-159-168
Abstract
Objective. To evaluate the efficacy and safety of rituximab (RTM) treatment in the long-term follow-up of patients with systemic lupus erythematosus (SLE) refractory to standard therapy.
Material and methods. RTM therapy was prescribed to 97 SLE patients with high disease activity and insufficient effica- cy of using high doses of glucocorticoids (GC) and cytostatics. The median follow-up time (25th; 75th percentiles) was 18 [12; 36] months. The most common clinical manifestations of SLE included nephritis (62%), skin lesion (33%), and lesion of the nervous system (22.7%). The clinical assessment of the SLE activity was carried out using the SLEDAI-2K activity index. In assessing the therapy efficacy, the following concepts were used: the partial response (PR), complete response (CR), and flare. Flare was classified as moderate (MF) and severe (SF) using the SLE flare index (SFI). Results. Immediately after RTM therapy, depletion of B-cells was determined in 78% of the patients with SLE. During the 6-year follow-up, the effect of RTM therapy was achieved in 84% of the patients after repeated courses of RTM (CR – 56%, PR – 28%). In total, flares were observed in 24 (24.7%) patients; the median interval from RTM administration to flare was 12 [12; 24] months. In the long-term follow-up, the decline in the SLEDAI-2K index, normalization of laboratory test values, and the decrease in the daily GC dose were noted. Most patients tolerated well both the first and repeated courses of RTM therapy.
Conclusion. According to the results of the long-term follow-up, RTM therapy is a highly effective method to treat SLE patients with the ineffectiveness of previously conducted standard therapy with GC and cytostatics. Good tolerance of RTM treatment has been noted; no increase in risk of infectious complications or adverse reactions has been found.
About the Authors
M. E. Tsanyan
V.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
S. K. Soloviev
V.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
A. V. Torgashina
V.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
E. N. Aleksandrova
V.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
S. G. Radenska-Lopovok
V.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
E. V. Nikolaeva
V.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
References
1. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007;56(7):2344–51. DOI: http://dx.doi.org/10.1002/art.22665.
2. D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythe- matosus. Lancet. 2007;369(9561):587–96. DOI: http://dx.doi.org/10.1016/S0140-6736(07)60279-7.
3. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis. 1955;1(1):12–32. DOI: http://dx.doi.org/10.1016/0021- 9681(55)90018-7.
4. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: а com- parison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308. DOI: http://dx.doi.org/10.1097/01.md.0000091181.93122.55.
5. Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119(8):700–6. DOI: http://dx.doi.org/10.1016/j.amjmed.2005.11.034.
6. Heller T, Ahmed M, Siddiqqi A, et al. Systemic lupus erythematosus in Saudi Arabia: Morbidity and mortality in a multiethnic pop- ulation. Lupus. 2007;16(11):908–14. DOI: http://dx.doi.org/10.1177/0961203307081112.
7. Eder L, Urowitz MB, Gladman DD. Damage in lupus patients – what have we learned so far? Lupus. 2013;22(12):1225–31. DOI: http://dx.doi.org/10.1177/0961203313492872.
8. Mok CC, Kwok CL, Ho LY, et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011;63(5):1182–9. DOI: 10.1002/art.30277.
9. Odendah M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus.
10. J Immunol. 2000;165(10):5970–9.
11. Chambers SA, Isenberg DA. Anti-B cell therapy (Rituximab) in the treatment of autoimmune disease. Lupus. 2005;14(3):210–4. DOI: http://dx.doi.org/10.1191/0961203305lu2138oa.
12. Silverman GJ. Anti-CD20 therapy in systemic lupus erythemato- sus: a step closer to the clinic. Arthritis Rheum. 2005;52:371–7. DOI: http://dx.doi.org/10.1002/art.20857.
13. Isenberg DA. Rituximab – it was the best of times, it was the worst of times. Autoimmun Rev. 2012;11(11):790–1. DOI: 10.1016/j.autrev.2012.02.005.
14. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46(10):2673–7. DOI: http://dx.doi.org/10.1002/art.10541.
15. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum. 2009;61(4):482–7. DOI: http://dx.doi.org/10.1002/art.24341.
16. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a lon- gitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44(12):1542–5. DOI:10.1093/rheumatology/kei080.
17. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006;2(1):20–7. DOI: http://dx.doi.org/10.1038/ncprheum0042.
18. Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56(4):1263–72. DOI: http://dx.doi.org/10.1002/art.22505.
19. Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006;65(7):942–5. DOI: http://dx.doi.org/10.1136/ard.2005.044487. Epub 2005 Nov 3.
20. Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predic- tors of response. Ann Rheum Dis. 2007;66(9):1259–62. DOI: http://dx.doi.org/10.1136/ard.2006.067124. Epub 2007 Apr 5.
21. Patel DD. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum. 2002;46(8):1984–5. DOI: http://dx.doi.org/10.1002/art.10476.
22. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007;17(3):191–7. Epub 2007 Jun 20.
23. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011;20(7):709–16. DOI: 10.1177/0961203310395802. Epub 2011 Apr 8.
24. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of ritux- imab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26. DOI: 10.1002/art.34359. Epub 2012 Jan 9.
25. Gunnarsson I, Jonsdottir T. Rituximab treatment in lupus nephri- tis – where do we stand? Lupus. 2013;22(4):385–92. DOI: 10.1177/0961203312471574.
26. Catapano F, Chaudhry AN, Jones RB, et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25(11):3586–92. DOI: 10.1093/ndt/gfq256. Epub 2010 May 11.
27. Насонова ВА. Системная красная волчанка. Москва; 1972. [Nasonova VA. Sistemnaya krasnaya volchanka [Systemic lupus erythematosus]. Moscow; 1972.]
28. Насонова ВА, Астапенко МГ. Клиническая ревматология. Москва: Медицина; 1989. 320 c. [Nasonova VA, Astapenko MG. Klinicheskaya revmatologiya [Clinical rheumatology]. Moscow: Meditsina; 1989. 320 c.]
29. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythe- matosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.
30. Соловьев СК, Торгашина АВ, Насонов ЕЛ. Эффективность ритуксимаба при системной красной волчанке.
31. В кн.: Анти-В-клеточная терапия в ревматологии: фокус
32. на ритуксимаб. Под ред. Е.Л. Насонова. Москва: ИМА-ПРЕСС; 2012. С.153–62. [Solov'evSK,TorgashinaAV, NasonovEL. Efficiency of rituksimab in systemic lupus erythe- matosus. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na
33. rituksimab [Anti-B-cell therapy in rheumatology: focus on rituk- simab]. Nasonov EL, editor. Moscow: IMA-PRESS; 2012. P.153–62.]
34. Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol. 2006;24(43):99–104.
35. Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis. 2007;66(3):61–4.
36. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs. 1999;58(1):79–88. DOI: http://dx.doi.org/10.2165/00003495- 199958010-00009.
37. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):143–50. DOI: http://dx.doi.org/10.1136/ard.2006.061002. Epub 2006 Oct 26.
38. Fernandes-Nebro A, de la Fuente JM, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus. 2012;21(10):1063–76. DOI: http://dx.doi.org/10.1177/0961203312446627.
39. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of ritux- imab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458–66. DOI: http://dx.doi.org/10.1002/art.27541.
40. Witt M, Grunke M, Proft F, et al. Clinical outcomes nd safety of rituximab treatment for patients with systemic lupus erythemato- sus (SLE) – results from a nationwide cohort in Germany (GRAID). Lupus. 2013;22(11):1142–9. DOI: http://dx.doi.org/10.1177/0961203313503912.
41. Smith KG, Jones RB, Burns SM, Jayne DRW. Long-term com- parison of rituximab treatment for refractory systemic lupus ery- thematosus and vasculitis. Remission, relapse and re-treatment. Athritis Rheum. 2006;54(9):2970–82.
42. Мendoza CA, Valdes RM, Orta EC, et al. Treating severe systemic lupus erythematosus with rituximab. An open study. Rheumatol Clin. 2009;5(4):147–52.
43. Perez MV, Castro BH, Saharopulos OP, et al. Clinical and immunological effects of Rituximab in patients with lupus nephri- tis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83. DOI: http://dx.doi.org/10.1186/ar1954. Epub 2006 May 5.
44. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913–20. DOI: http://dx.doi.org/10.1136/ard.2004.029694.
45. Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56(4):1263–72. DOI: http://dx.doi.org/10.1002/art.22505.
46. Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effect of rituximab-based depletion therapy on skin manifestations of lupus erythematosus – report of 17 cases and review of the literature. Lupus. 2013;22(9):932–9. DOI: http://dx.doi.org/10.1177/0961203313497115.
47. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythe- matosus. Arthritis Rheum. 2004;50(11):3580–90. DOI: http://dx.doi.org/10.1002/art.20592.
48. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46(10):2673–7. DOI: http://dx.doi.org/10.1002/art.10541.
49. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a lon- gitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44(12):1542–5. DOI: http://dx.doi.org/10.1093/rheumatol- ogy/kei080. Epub 2005 Sep 27.
Review
For citations:
Tsanyan M.E., Soloviev S.K., Torgashina A.V., Aleksandrova E.N., Radenska-Lopovok S.G., Nikolaeva E.V., Nasonov E.L. RITUXIMAB TREATMENT EFFICACY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS REFRACTORY TO STANDARD THERAPY IN THE LONG-TERM FOLLOW-UP. Rheumatology Science and Practice. 2014;52(2):159-168. (In Russ.) https://doi.org/10.14412/1995-4484-2014-159-168
Views:
1166
Email this article 